We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, EMA Extend Joint Inspection Initiative to Generic Applications
FDA, EMA Extend Joint Inspection Initiative to Generic Applications
The FDA and EMA will expand their joint inspection activities to include facilities involved with bioequivalence studies for generic drug applications.